Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in ALS
NCT03506425Phase 2Completed
- Start
- Jun 2018
- Primary completion
- Mar 2019
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of triheptanoin in amyotrophic lateral sclerosis (ALS) (3 arms). Primary endpoint: ALS Functional Rating Scale-revised Slope at 6 months. Started Jun 2018; status: completed.
02
Drugs
triheptanoin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03506425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506425.